世界の mRNA がんワクチン市場の臨床的および商業的状況は、投資の急増、戦略的提携、がん治療における画期的な進歩への期待を特徴とする変革的な変化を迎えています。製薬企業やバイオテクノロジー企業が mRNA 技術の可能性を認識するにつれて、前例のない精度でがんを標的とする画期的な治療法を開発する可能性を刺激して、熾烈な競争が徐々に繰り広げられています。
目次
1. mRNA Vaccines as Next Generation Cancer Immunotherapy
1.1 mRNA Vaccines Overview
1.2 mRNA Vaccines v/s Other Cancer Therapeutic Approaches
1.3 mRNA Vaccines v/s Other Vaccines
2. Global mRNA Cancer Vaccines Market Overview
2.1 Current Market Landscape
2.2 Future Clinical and Commercialization Opportunities
3. Global mRNA Cancer Vaccines Market Trends by Country
3.1 US
3.2 China
3.3 Australia
3.4 Europe
3.5 Canada
4. Global mRNA Cancer Vaccines Market Collaborations, Deals and Investments
5. Global mRNA Cancer Vaccines Market Clinical Landscape by Indication
5.1 Breast Cancer
5.2 Brain Cancer
5.3 Melanoma
5.4 Colorectal Cancer
5.5 Head and Neck Cancers
6. Global mRNA Cancer Vaccines Clinical Pipeline Overview
6.1 By Company
6.2 By Country
6.3 By Patient Segment
6.4 By Phase
6.5 By Priority Status
7. Global mRNA Cancer Vaccines Clinical Pipeline By Company, Indication and Phase
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-II/III
7.7 Phase-III
8. Proprietary Technologies and Methodologies for RNA Cancer Vaccines Development
8.1 FixVac - BioNTech
8.2 iNeST - BioNTech
8.3 NanoReady - Samyang Holdings
8.4 CureVac Method - CureVac
8.5 mRNA platform - Moderna
8.6 NeoCura Ag - NeoCura
9. Competitive Landscape
9.1 Avstera Therapeutics
9.2 BioNTech
9.3 Combined Therapeutics
9.4 CureVac
9.5 EpiVax
9.6 Immorna
9.7 Immune Design
9.8 MDimune
9.9 Moderna Therapeutics
9.10 NeoCura
9.11 Orna Therapeutics
9.12 pHion Therapeutics
9.13 Regen BioPharma
9.14 RNAimmune
9.15 TransCode Therapeutics
List of Figures
Figure 5-1: KEYNOTE-603 Phase I Study - Initiation and Completion Years
Figure 5-2: GO39733 Phase I Study - Initiation and Completion Years
Figure 5-3: ATTAC-II Phase II Study - Initiation and Completion Years
Figure 5-4: CV-GBLM-001 Phase I Study - Initiation and Completion Years
Figure 5-5: GO39733 Phase II Study - Initiation and Completion Years
Figure 5-6: BNT111-01 Phase II Study - Initiation and Completion Years
Figure 5-7: BNT122-01 Phase II Study - Initiation and Completion Years
Figure 5-8: AHEAD-MERIT Phase II Study - Initiation and Completion Years
Figure 5-9: KEYNOTE-603 Phase II Study - Initiation and Completion Years
Figure 6-1: Global - mRNA Cancer Vaccines Clinical Pipeline by Company (Numbers), 2023
Figure 6-2: Global - mRNA Cancer Vaccines Clinical Pipeline by Country (Numbers), 2023
Figure 6-3: Global - mRNA Cancer Vaccines Clinical Pipeline by Patient Segment (Numbers), 2023
Figure 6-4: Global - mRNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2023
Figure 6-5: Global - mRNA Cancer Vaccines Clinical Pipeline by Priority Status (Numbers), 2023
Figure 8-1: BioNTech - uRNA products
Figure 8-2: BioNTech - iNeST technology
Figure 8-3: CureVac - CureVac Method for Generation of mRNA Therapeutics
Figure 8-4: Moderna - mRNA Technology
Figure 8-5: NeoCura - NeoCura Ag Platform
List of Tables
Table 1-1: mRNA Vaccines v/s Other Cancer Therapeutic Approaches
Table 1-2: mRNA-Based Cancer Vaccines vs. Other Cancer Vaccines
Table 2-1: Recent Designations Granted to Investigational mRNA Cancer Vaccines
Table 5-1: Breast Cancer mRNA Vaccines in Clinical Trials
Table 5-2: Brain Cancer mRNA Vaccines in Clinical Trials
Table 5-3: Melanoma mRNA Vaccines in Clinical Trials
Table 5-4: Colorectal Cancer mRNA Vaccines in Clinical Trials
Table 5-5: Head and Neck Cancer mRNA Vaccines in Clinical Trials
